Comparative Pharmacology
Head-to-head clinical analysis: IMPLANON versus LUNELLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMPLANON versus LUNELLE.
IMPLANON vs LUNELLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Etonogestrel, a progestin, binds to progesterone and androgen receptors, suppressing gonadotropin release (FSH, LH) and preventing ovulation. It also increases cervical mucus viscosity, impeding sperm penetration, and alters endometrial morphology.
Lunelle is a combination contraceptive injection containing medroxyprogesterone acetate and estradiol cypionate. It suppresses gonadotropin secretion, inhibiting ovulation and thickening cervical mucus to prevent sperm penetration.
Insert 1 rod (68 mg etonogestrel) subdermally in the inner upper arm; replacement every 3 years.
150 mg intramuscular injection on day 5 of menstrual cycle, then every 90 days thereafter.
None Documented
None Documented
Terminal elimination half-life is approximately 25-30 hours; significant interindividual variability
Terminal elimination half-life of 20-30 hours in healthy adults; prolonged to 40-60 hours in moderate renal impairment (CrCl 30-50 mL/min). Clinically, steady state reached in 4-5 days.
Metabolites primarily excreted in urine (approximately 50%) and feces (30-35%)
Primarily renal (~70% as unchanged drug and inactive metabolites), with ~20% biliary/fecal elimination. Minimal dose recovered in feces as parent compound.
Category C
Category C
Contraceptive
Contraceptive